A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

NCT05448599 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: 6MW3211 injection with Intravenous Infusion

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.